The TRAIL-1 study explores the use of pirfenidone, an antifibrotic agent approved for idiopathic pulmonary fibrosis, in patients with rheumatoid arthritis-associated interstitial lung disease.
The ORAL Strategy randomized controlled trial evaluates the effect of LZV on HZ rates in rheumatoid arthritis patients who respond inadequately to methotrexate and are treated with biologics.
A new study helps physicians understand how patients analyze the costs and benefits of RA treatments so that they can better engage patients in shared decision-making.
Recent work on the biology of IL-6 has demonstrated a key role in a wide variety of bodily systems including vascular, lipid metabolism, insulin resistance and neuropsychological behavior.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Translational work combining human plasma studies and previous mouse model data will enable identification of new, precise biomarkers and potential treatment pathways that may help pinpoint and treat RA and PsA patients at increased risk of CV disease.
When might joint pain be Whipple disease? Cleveland Clinic gastroenterologists explain.